Reports world wide Gastrointestinal Stromal Tumor (GIST) | Page 2

EPIDEMIOLOGY
MARKETED DRUGS
Approvals by country
PIPELINE DRUGS IN THE US
KEY REGULATORY EVENTS
Blueprint Lays Out Path To Early Approval In Small GIST Population
PARENT PATENTS
REVENUE OPPORTUNITY
CLINICAL TRIAL LANDSCAPE
Sponsors by status
Sponsors by phase
BIBLIOGRAPHY
Prescription information:
APPENDIX
LIST OF FIGURES
Figure 1: Trends in incident cases of gastrointestinal stromal tumor, 2016–25
Figure 2: Pipeline drugs for gastrointestinal stromal tumor in the US
Figure 3: Pipeline drugs for gastrointestinal stromal tumor, by company
Figure 4: Pipeline drugs for gastrointestinal stromal tumor, by drug type
Figure 5: Pipeline drugs for gastrointestinal stromal tumor, by classifications
Figure 6: Parent patents in gastrointestinal stromal tumor
Figure 7: Clinical trials in gastrointestinal stromal tumor
Figure 8: Top 10 drugs for clinical trials in gastrointestinal stromal tumor
Figure 9: Top 10 companies for clinical trials in gastrointestinal stromal tumor
Figure 10: Trial locations in gastrointestinal stromal tumor
Figure 11: Gastrointestinal stromal tumor trials status
Figure 12: Gastrointestinal stromal tumor trials sponsors, by phase
LIST OF TABLES
Table 1: Incident cases of gastrointestinal stromal tumor, 2016–25
Table 2: Incidence rates of gastrointestinal stromal tumor, 2016–25
Table 3: Marketed drugs for gastrointestinal stromal tumor
Table 4: Approvals by country for gastrointestinal stromal tumor
Table 5: Pipeline drugs for gastrointestinal stromal tumor in the US
Table 6: Historical global sales, by drug ($m), 2012–16
Table 7: Forecasted global sales, by drug ($m), 2017–22
Ask to Expertise @
https://www.reportsworldwide.com/enquiry?report_id=42614
About US:
Reportsworldwide.com is a one stop shop for all market intelligence needs. Our database of
market research reports provides in depth coverage of 12 top industry verticals worldwide.
We help you meet your market intelligence needs by mapping it with our database of
market research reports including.